|
| Press Releases |
|
 |
|
| Wednesday, June 28, 2017 |
|
|
Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 16th consecutive year since its initial inclusion in 2002. more info >> |
|
| Tuesday, June 27, 2017 |
|
|
Eisai Temporarily Withdraws New Drug Application for Anticancer Agent Halaven in China |
| Eisai Co., Ltd. announced today that, in alignment with Chinese regulations, it has temporarily withdrawn its new drug application for anticancer agent eribulin mesylate (Brand name: Halaven) in China in order to submit additional documentation. more info >> |
|
| Friday, June 23, 2017 |
|
|
Eisai Submits Application for Additional Indication of Anticancer Agent Lenvima for Hepatocellular Carcinoma in Japan |
| Eisai Co., Ltd. announced today that it has submitted an application for an additional indication of its in-house discovered and developed anticancer agent Lenvima (generic name: lenvatinib mesylate) for the treatment of hepatocellular carcinoma (HCC) in Japan, the first in the world. more info >> |
|
|
Cardiovascular Outcomes Trial of Anti-Obesity Agent Lorcaserin to Continue Based on Recommendation of Independent Data Monitoring Committee After Completion of Interim Safety Analysis |
| Eisai Co., Ltd. has announced that it has received a recommendation from an independent Data Monitoring Committee to continue the ongoing Cardiovascular Outcomes Trial of lorcaserin hydrochloride after the completion of a pre-specified interim safety analysis, evaluating the incidence of Major Adverse Cardiovascular Events (MACE), defined as cardiovascular death, myocardial infarction or stroke. more info >> |
|
| Thursday, June 8, 2017 |
|
|
Launch of Pain Treatment Lyrica OD Tablet Formulation in Japan |
| Pfizer Japan Inc. and Eisai Co., Ltd. have announced that Lyrica OD Tablets 25mg, 75mg, 150mg (OD tablet: orally disintegrating tablet), a new formulation following pain treatment Lyrica Capsules (pregabalin). more info >> |
|
| Monday, June 5, 2017 |
|
|
Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-Line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that the results of a Phase III trial (Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylate against the comparator sorafenib as first-line treatment for unresectable hepatocellular carcinoma, will be orally presented during the 53rd Annual Meeting of ASCO. more info >> |
|
|
Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab |
| Eisai Co., Ltd. announced the first results for metastatic endometrial carcinoma obtained from a Phase Ib/II study (Study 111) of its in-house developed multi-kinase inhibitor lenvatinib mesylate in combination with the MSD anti-PD-1 antibody pembrolizumab (brand name: KEYTRUDA), during a presentation at the 53rd Annual Meeting of ASCO. more info >> |
|
| Thursday, June 1, 2017 |
|
|
Eisai Commits Funding to the 2nd Phase of Global Health Innovative Technology Fund Activities |
| Eisai Co., Ltd. has announced that it will grant a total of 500 million yen to the Global Health Innovative Technology Fund (GHIT Fund) to fund the second phase of its activities, which will take place in the five-year period from FY 2018 to FY 2022. more info >> |
|
| Wednesday, May 31, 2017 |
|
|
Eisai Enters Into a New Joint Research Agreement With the Broad Institute to Develop an Antimalarial Medicine |
| Eisai Co., Ltd. announced today that it has entered into a new joint research agreement with the Broad Institute, a collaborative research institute which includes researchers from the Massachusetts Institute of Technology and Harvard University to develop a new antimalarial medicine based on antimalarial drug targets the team identified last year. more info >> |
|
| Thursday, May 18, 2017 |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at 53rd ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results for its in-house discovered lenvatinib mesylate and eribulin mesylate, as well as H3B-8800 will be presented during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Mooreast Holdings Announces Business Update
Apr 25, 2025 10:00 HKT/SGT
|
|
|
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025
Apr 24, 2025 22:42 HKT/SGT
|
|
|
TransNusa Increases Scheduled Flight Frequency to Singapore
Apr 24, 2025 22:09 HKT/SGT
|
|
|
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
Apr 24, 2025 20:49 HKT/SGT
|
|
|
君圣泰医药三项创新研究成果即将亮相2025欧肝会(EASL)
Apr 24, 2025 18:35 HKT/SGT
|
|
|
MyJCB App Wins "iF DESIGN AWARD 2025"
Apr 24, 2025 17:00 JST
|
|
|
Honda、2025年3月度 四輪車 生産・販売・輸出実績を発表
Apr 24, 2025 15:15: JST
|
|
|
トヨタ、米国ウェストバージニア工場に8,800万ドルを追加投資
Apr 24, 2025 14:30: JST
|
|
|
MHIEC Completes Renovation of Core Facilities for Arita Municipal Recycle Plaza in Saga Prefecture
Apr 24, 2025 15:01 JST
|
|
|
トヨタ、2024年度 販売・生産・輸出実績を発表
Apr 24, 2025 13:35: JST
|
|
|
Earth Day Special: foundit Report Reveals 27% Surge in Green Jobs as Singapore Accelerates Sustainability Push
Apr 24, 2025 13:00 HKT/SGT
|
|
|
AI產業延續高景氣 明略科技講出企業級「DeepSeek+Manus」好故事
Apr 24, 2025 10:50 HKT/SGT
|
|
|
AI产业延续高景气 明略科技讲出企业级「DeepSeek+Manus」好故事
Apr 24, 2025 10:44 HKT/SGT
|
|
|
NEC invests in U.S.-based "Geodesic Alliance Fund" aiming to strengthen economic security business
Apr 24, 2025 10:23 JST
|
|
|
MHI Thermal Systems Wins German Red Dot Design Award 2025
Apr 24, 2025 10:11 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
